logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Mohammed T Qatanani

USPTO Granted Patents = 52 

Average Co-Inventor Count = 4.1

ph-index = 23

Forward Citations = 1,132(Granted Patents)

Forward Citations (Not Self Cited) = 25(Dec 10, 2025)


Company Filing History:

goldMedal52 out of 52 
 
Dyne Therapeutics, Inc.
 patents

Years Active: 2021-2025

Loading Chart...
Areas of Expertise:
Anti-Transferrin Receptor Antibody
Oligonucleotide Delivery
Muscle Targeting Complexes
Dystrophinopathies
Myotonic Dystrophy
Facioscapulohumeral Muscular Dystrophy
Exon Skipping
Duchenne Muscular Dystrophy
Therapeutic Formulations
Complexes for Muscle Disorders
RNA Targeting
Intravenous Delivery Methods
52 patents (USPTO):Explore Patents
1. 12460011 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering an oligonucleotide to a subject (2025-11-04),
2. 12440575 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-10-14),
3. 12440574 - Muscle targeting complexes and formulations for treating myotonic dystrophy (2025-10-14),
4. 12428487 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject (2025-09-30),
5. 12403203 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-09-02),
6. 12397062 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-08-26),
7. 12370264 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject (2025-07-29),
8. 12357703 - Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping (2025-07-15),
9. 12329825 - Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject (2025-06-17),
10. 12329824 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-06-17),
11. 12325753 - Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy (2025-06-10),
12. 12319743 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject (2025-06-03),
13. 12280122 - Muscle targeting complexes and uses thereof for treating myotonic dystrophy (2025-04-21),
14. 12263225 - Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy (2025-04-01),
15. 12239717 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-03-04),

Title: The Innovative Journey of Mohammed T Qatanani

Introduction: Mohammed T Qatanani is a pioneering inventor based in Waltham, MA (US) known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Mohammed T Qatanani holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: With a career spanning over two decades, Mohammed T Qatanani has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Mohammed T Qatanani has collaborated with top engineers, scientists, and researchers from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Mohammed T Qatanani's relentless pursuit of innovation and his passion for creating solutions that make a difference have solidified his reputation as a visionary inventor in the field of technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…